Inozyme Pharma, Inc. (INZY) Retained Earnings (Accumulated Deficit) USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Inozyme Pharma, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2019 to 2024.
  • Inozyme Pharma, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was -$309 M, a 33.2% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 -$309 M -$77.1 M -33.2% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$286 M -$71.2 M -33.1% Dec 31, 2023 10-Q 2024-05-07
Q3 2023 -$264 M -$68.2 M -34.7% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$248 M -$67.9 M -37.8% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$232 M -$67.6 M -41.1% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 -$215 M -$67.1 M -45.4% Dec 31, 2022 10-K 2024-03-12
Q3 2022 -$196 M -$67.3 M -52.2% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$180 M -$65.2 M -56.8% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 -$165 M -$62.5 M -61.2% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 -$148 M -$56.6 M -62.2% Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$129 M -$49 M -61.3% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 -$115 M -$62.8 M -121% Jun 30, 2021 10-Q 2021-08-11
Q1 2021 -$102 M Mar 31, 2021 10-Q 2021-05-12
Q4 2020 -$91.1 M -$56.4 M -163% Dec 31, 2020 10-K 2022-03-15
Q3 2020 -$80 M Sep 30, 2020 10-Q 2020-11-12
Q2 2020 -$51.9 M Jun 30, 2020 10-Q 2020-09-03
Q4 2019 -$34.7 M Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.